孙飘扬打赢翻身仗财富年增40亿 恒瑞医药“A+H”上市加速出海

Core Viewpoint - Heng Rui Medicine has officially entered the "A+H" dual-platform listing era, marking a significant milestone in its internationalization strategy and financial strengthening [2][3]. Group 1: Company Overview - Heng Rui Medicine, founded by Sun Piaoyang, has transformed from a small pharmaceutical factory into a leading pharmaceutical giant over the past 30 years [10]. - The company has successfully recovered its market position and increased its market capitalization to over 300 billion yuan, following a strategic shift towards innovative drugs and international expansion [2][6]. Group 2: Financial Performance - In the first quarter of 2025, Heng Rui Medicine achieved a revenue of 7.206 billion yuan, representing a year-on-year growth of 20.14%, and a net profit of 1.874 billion yuan, with a growth rate of 36.9%, marking the highest net profit growth in nearly a decade [9]. - The company's revenue and net profit have consistently increased from 2004 to 2020, with revenue rising from 1.145 billion yuan to 27.735 billion yuan, and net profit from 123 million yuan to 6.328 billion yuan [6]. Group 3: Strategic Developments - The recent listing on the Hong Kong Stock Exchange is a crucial step for Heng Rui Medicine to accelerate its internationalization and enhance its financial resources [3][10]. - The company has engaged in 15 licensing transactions with global partners from 2018 to 2024, indicating a strong commitment to international collaboration and innovation [9]. Group 4: Leadership and Future Outlook - Sun Piaoyang, after stepping down as chairman in 2020, returned to lead the company in 2021, focusing on innovative drugs and international expansion [8][9]. - The market is keenly observing how Heng Rui Medicine will continue to navigate the competitive landscape of the pharmaceutical industry, especially with emerging competitors like BeiGene and others [10].